BridgeBio Pharma, Inc.
(NASDAQ: BBIO)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

79.820 -

+6.490 (+8.85%)
价格区间 78.950 - 84.940   (7.59%)
开盘 84.845
昨收 73.330
79.810
买盘 208
79.920
卖盘 220
成交量 4,294,025
成交额 266,341,560
注释 -
数据延迟。最后一次更新12 Feb 2026 23:50.
数据提供商
查看所有活动


Loading Chart...

Please login to view stock data and analysis